The effect of dapagliflozin on a ventricular arrhythmia or sudden death seemed to be more consistent regarding aetiology (non-ischaemic vs. ischaemic) and baseline MRA therapy (we did not perform a subgroup analysis for renin-angiotensin system blockers or beta-blockers because >90% of participants were receiving both of these therapies). This evidence concerns the gene REN and Ventricular arrhythmia.